Healthcare provider profile · identity verified

Jean Robert Darbouze, MD

Internal Medicine · JERSEY CITY, NJ · NPI 1639201510

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Rosuvastatin Calcium	Rosuvastatin Calcium	277	60
Amlodipine Besylate	Amlodipine Besylate	255	55
Metoprolol Tartrate	Metoprolol Tartrate	237	41
Pantoprazole Sodium	Pantoprazole Sodium	213	45
Metformin Hcl	Metformin Hcl	205	44
Furosemide	Furosemide	200	42
Tamsulosin Hcl	Tamsulosin Hcl	185	40
Hydralazine Hcl	Hydralazine Hcl	173	35
Gabapentin	Gabapentin	156	38
Hydrochlorothiazide	Hydrochlorothiazide	139	31
Montelukast Sodium	Montelukast Sodium	126	33
Clopidogrel	Clopidogrel Bisulfate	124	25
Atorvastatin Calcium	Atorvastatin Calcium	110	24
Losartan Potassium	Losartan Potassium	102	20
Eliquis	Apixaban	100	16
Baclofen	Baclofen	99	36
Famotidine	Famotidine	99	23
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	95	36
Carvedilol	Carvedilol	93	18
Levothyroxine Sodium	Levothyroxine Sodium	83	14
Fenofibrate	Fenofibrate,micronized	79	23
Glipizide	Glipizide	78	21
Simvastatin	Simvastatin	72	12
Albuterol Sulfate Hfa	Albuterol Sulfate	70	18
Alendronate Sodium	Alendronate Sodium	70	18
Nabumetone	Nabumetone	69	30
Clonidine Hcl	Clonidine Hcl	66	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	55	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	54	19
Glimepiride	Glimepiride	54	suppressed
Linzess	Linaclotide	51	suppressed
Sertraline Hcl	Sertraline Hcl	51	14
Azithromycin	Azithromycin	48	37
Allopurinol	Allopurinol	47	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	47	suppressed
Meloxicam	Meloxicam	46	17
Diclofenac Sodium	Diclofenac Sodium	45	18
Januvia	Sitagliptin Phosphate	45	12
Fenofibrate	Fenofibrate Nanocrystallized	44	suppressed
Acarbose	Acarbose	41	suppressed
Trazodone Hcl	Trazodone Hcl	41	12
Lisinopril	Lisinopril	40	suppressed
Meclizine Hcl	Meclizine Hcl	40	16
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	38	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	38	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	37	suppressed
Finasteride	Finasteride	37	suppressed
Myrbetriq	Mirabegron	37	suppressed
Fluticasone Propionate	Fluticasone Propionate	35	21
Isosorbide Mononitrate Er	Isosorbide Mononitrate	35	suppressed
Pregabalin	Pregabalin	35	12
Risperidone	Risperidone	35	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	33	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	28	suppressed
Etodolac	Etodolac	27	suppressed
Megestrol Acetate	Megestrol Acetate	27	suppressed
Metformin Hcl Er	Metformin Hcl	27	suppressed
Latanoprost	Latanoprost	26	suppressed
Jardiance	Empagliflozin	25	suppressed
Valproic Acid	Valproic Acid	25	suppressed
Methimazole	Methimazole	24	suppressed
Topiramate	Topiramate	24	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	23	12
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	23	suppressed
Warfarin Sodium	Warfarin Sodium	23	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	22	13
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	22	suppressed
Lactulose	Lactulose	22	suppressed
Sucralfate	Sucralfate	22	suppressed
Terazosin Hcl	Terazosin Hcl	22	suppressed
Ammonium Lactate	Ammonium Lactate	21	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	21	suppressed
Donepezil Hcl	Donepezil Hcl	21	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	21	13
Nebivolol Hcl	Nebivolol Hcl	20	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	19	13
Naproxen	Naproxen	19	suppressed
Nifedipine Er	Nifedipine	19	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	18	suppressed
Omeprazole	Omeprazole	18	suppressed
Metoprolol Succinate	Metoprolol Succinate	17	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	17	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	17	suppressed
Brimonidine Tartrate	Brimonidine Tartrate	16	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	16	suppressed
Edarbyclor	Azilsartan Med/Chlorthalidone	16	suppressed
Insulin Lispro Protamine Mix	Insulin Lispro Protamin/Lispro	16	suppressed
Isosorbide Dinitrate	Isosorbide Dinitrate	16	suppressed
Lansoprazole	Lansoprazole	16	suppressed
Novolog Flexpen	Insulin Aspart	15	suppressed
Ropinirole Hcl	Ropinirole Hcl	15	suppressed
Atenolol	Atenolol	14	suppressed
Farxiga	Dapagliflozin Propanediol	14	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	14	suppressed
Tramadol Hcl	Tramadol Hcl	14	suppressed
Celecoxib	Celecoxib	13	suppressed
Prednisone	Prednisone	13	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	12	suppressed
Amantadine	Amantadine Hcl	12	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	12	suppressed
Ezetimibe	Ezetimibe	12	suppressed
Folic Acid	Folic Acid	12	suppressed
Spironolactone	Spironolactone	12	suppressed
Cyproheptadine Hcl	Cyproheptadine Hcl	11	suppressed
Divalproex Sodium	Divalproex Sodium	11	suppressed
Divalproex Sodium Er	Divalproex Sodium	11	suppressed
Dorzolamide-Timolol	Dorzolamide Hcl/Timolol Maleat	11	suppressed
Entacapone	Entacapone	11	suppressed
Humalog Kwikpen U-100	Insulin Lispro	11	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	11	suppressed
Lubiprostone	Lubiprostone	11	suppressed
Phenobarbital	Phenobarbital	11	suppressed
Telmisartan-Hydrochlorothiazid	Telmisartan/Hydrochlorothiazid	11	suppressed
Triumeq	Abacavir/Dolutegravir/Lamivudi	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error